Stock comparison
IRadimed
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IRMD
IRadimed
Market cap
$1.18B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
IRadimed IRMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IRMD | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 68B | 69B | MTD |
| Benjamin Graham | 89A | 65B | IRMD |
| Philip Fisher | 92A | 63C | IRMD |
| Peter Lynch | 76B | 66B | IRMD |
| Joel Greenblatt | 65C | 68B | MTD |
| Charlie Munger | 78B | 74B | IRMD |
| Terry Smith | 75B | 70B | IRMD |
Side-by-side metrics
| Metric | IRMD | MTD |
|---|---|---|
| Market cap | $1.18B | $22.29B |
| P/E (TTM) | 50.4x | 25.3x |
| EV/EBIT | 43.4x | 21.6x |
| ROIC (TTM) | 21.38% | 36.09% |
| Gross margin | 76.84% | 57.79% |
| Net margin | 27.36% | 21.4% |
| Revenue CAGR 5y | 18.99% | 2.01% |
| EPS CAGR 5y | 23.53% | 6.12% |
| Debt / Equity | - | - |
| Dividend yield | 1.33% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IRMD leads on
- Dividend yield1.33%vs 0.0%+100%
- Revenue CAGR 5y18.99%vs 2.01%+89%
- EPS CAGR 5y23.53%vs 6.12%+74%
- Gross margin76.84%vs 57.79%+25%
MTD leads on
- Debt / Equity-vs -+100%
- Market cap$22.29Bvs $1.18B+95%
- EV/EBIT21.6xvs 43.4x+50%
- P/E (TTM)25.3xvs 50.4x+50%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.